Enhancing Electronic Health Record Data Quality

By Michael Awood

September 6, 2023

Electronic Health Record (EHR) data in biomedical research has seen a significant surge, especially during the COVID-19 pandemic. These rich data records are perfect for complex analyses, including machine learning and artificial intelligence. However, the quality of this data has drawn much concern.

Despite the critical role EHR data plays in healthcare and its frequent use in biomedical research, its quality is often overlooked. This presents a need for a standardised approach to evaluate EHR data quality.

In 1996, Wang and Strong proposed a data quality framework that covered intrinsic, contextual, representational, and accessible data quality. They highlighted that poor data quality could have social and economic impacts. Although their study was not healthcare-specific, their framework focused on the needs of data users, providing a unique perspective.

A 2013 review identified five aspects of EHR data quality – completeness, correctness, concordance, plausibility, and currency. They evaluated these aspects through seven methods, including a gold standard comparison and data element agreement. However, the definitions of these methods and dimensions often overlapped, indicating the need for a more standardised approach. Other data quality frameworks have been suggested, but they differ in their recording and discussion methods. This shows a lack of consensus and adoption.

The development of automated tools for data quality assessment holds the potential to address the data quality challenge. These tools could streamline the process and enhance efficiency. The article suggests that future research should aim at creating tools that improve data integrity and reliability in patient care and research. The potential impact of this work is vast, with implications for disease tracking, patient care, and the advancement of medical science.

It is important that EHRs reflect true and accurate data to minimise potential downstream inefficiencies – due to poor data. This data also feeds into prediction analytics or algorithms for various AI systems, where poor data could result in incorrect analytics and poor outcomes. At present, there are numerous entry points to an EHR due to the multitude of records. Data sources include researchers, medical providers, and increasingly, patients through patient-reported outcome measures (PROMs). Utilising the framework by Wang and Strong could provide a better understanding of data needs, leading to improved health records and health information exchanges (HIEs).

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.